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Purpose. After allogeneic hematopoietic stem cell transplantation with nonmyeloablative con-
ditioning (NMHCT), many patients experience prolonged anemia and require red blood cell
(RBC) transfusions. We enrolled 60 consecutive patients undergoing NMHCT in a phase II
trial to determine the optimal utilization of recombinant human erythropoietin (rHuEPO)
therapy in this setting.
Patients and Methods. The first 14 NMHCT recipients did not receive rHuEPO (control
group). Nineteen patients were scheduled to start rHuEPO on day 0 (EPO group 2) and 27
patients on day 28 after the transplant (EPO group 1). RHuEPO was administered subcuta-
neously once weekly at a dose of 500 U/kg/wk with the aim of achieving hemoglobin (Hb)
levels of 13 g/dL. The 3 groups were well balanced for major characteristics.
Results. During the first month (p! 0.0001) as well as days 30 to 100 (p! 0.0001) and days
100 to 180 (p ! 0.0001), Hb values were higher in patients receiving rHuEPO compared to
those not receiving it. However, transfusion requirements were significantly decreased only
in the first month in EPO group 2 (p [ 0.0169). T-cell chimerism above 60% on day 42
was the best predictor of Hb response (p ! 0.0001) or Hb correction (p [ 0.0217), but my-
eloid chimerism above 90% also predicted for Hb response (p [ 0.0069). Hb response was
also decreased in patients receiving CD8-depleted grafts and increased in the few patients
not receiving TBI, but only in univariate analysis.
Conclusions. Anemia after NMHCT is sensitive to rHuEPO therapy, but less so than after
conventional allogeneic HCT. RHuEPO decreases transfusion requirements only in the first
30 days posttransplant. T-cell chimerism below 60% on day 42 impaired Hb response, sug-
gesting possible inhibition of donor erythropoiesis by residual recipient lymphocytes. A pro-
spective randomized trial should be performed with rHuEPO starting on the day of
transplantation to assess its clinical benefit in terms of transfusion requirements and quality
of life.  2006 International Society for Experimental Hematology. Published by Elsevier
Inc.Allogeneic hematopoietic cell transplantation (HCT) is
increasingly used in selected patients with hematological
malignancies [1]. Its curative potential is in part achieved
through an immune-mediated destruction of malignant cells
by donor lymphocytes termed the graft-vs-leukemia (GVL)
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doi: 10.1016/j.exphem.2006.04.012effect [2]. However, because of its toxicity, conventional al-
logeneic HCT is restricted to younger and fitter patients [1].
Therefore, several groups have developed the concept of re-
duced-intensity conditioning regimen [3–6] or truly non-
myeloablative HCT (NMHCT) [7–10], in which the main
mechanism of tumor eradication has been shifted from
high-dose cytotoxic agents to the graft-vs-tumor effects
[11]. Because of the mild conditioning regimen given and
the use of peripheral blood as the source of hematopoietic
stem cells (PBSC), posttransplant myelosuppression has
remained modest and transient after NMHCT [7,12,13].Experimental Hematology. Published by Elsevier Inc.
842 G. Vanstraelen et al./ Experimental Hematology 34 (2006) 841–850Erythropoietin (EPO) is the critical regulatory factor of
erythropoiesis. In patients with normal kidney function,
serum EPO levels increase exponentially when an anemia
develops [14]. The adequacy of EPO serum levels is best
assessed by the observed/predicted (O/P) ratio, a value
below 1 indicating that EPO production is lower than
expected for the degree of anemia [15]. After high-dose
chemotherapy, serum EPO levels first rapidly increase to
disproportionately high levels for 1 to 3 weeks, with peak
values usually observed in the first week after the condi-
tioning regimen [16–18]. However, after classical alloge-
neic HCT, the EPO response to anemia then generally
becomes impaired, resulting in inappropriately low EPO
levels and prolonged anemia [16–20]. Numerous trials
have shown that there is a major need for efficient erythro-
poiesis enhancement to alleviate chronic anemia and reduce
the high transfusion requirements after HCT. However, re-
combinant human erythropoietin (rHuEPO) therapy offers
minimal (in case of allogeneic HCT) or no (in case of au-
tologous HCT) benefit when rHuEPO is started immedi-
ately after the transplant [21–32]. On the other hand, we
have shown that rHuEPO was remarkably efficient when
started around day 30 after transplantation with a myeloa-
blative conditioning regimen, i.e., when endogenous EPO
production becomes impaired, and this was true for both
allogeneic [32] and autologous [20] HCT.
Contrary to conventional allogeneic HCT, NMHCT is
not associated with endogenous EPO deficiency [33].
Rather, EPO O/P ratios remain well within the normal
range over the whole posttransplant follow-up [33]. How-
ever, although both red blood cell (RBC) and platelet trans-
fusion requirements are reduced in NMHCT compared to
conventional PBSCT [12,34–36], many NMHCT recipients
experience prolonged anemia and many of them still re-
quire RBC transfusions [12,34,36]. A pilot study has shown
that early rHuEPO therapy could be effective in this setting
[37].
We report here on 60 consecutive patients undergoing
NMHCT. The first 14 patients did not receive rHuEPO
(control group). We then carried out a prospective trial of
rHuEPO therapy, starting on day 0 in a group of 19 patients
and on day 30 posttransplant in another group of 27
patients. The aim of this phase II trial was to examine the
potential of two schedules of rHuEPO therapy to correct




We studied 60 patients receiving a PBSC (n5 59) or marrow (n5
1) transplant after a nonmyeloablative conditioning regimen in
2002–2004 [12]. The minimal follow-up is 100 days. Patients’
characteristics are detailed in Table 1. Conditioning consisted of
2 Gy total-body irradiation (TBI) alone (n 5 24) or combinedwith 90 mg/m2 fludarabine for patients not heavily pretreated or
unrelated transplants (n 5 28) or fludarabine and 3 g/m2 cyclo-
phosphamide (Flu-Cy) when previous irradiation precluded the
use of TBI (n 5 8) (Table 1). Posttransplant immunosuppression
was carried out with cyclosporine (CsA) and mycophenolate mo-
fetil (MMF) as previously reported [12,38]. Transplants were un-
manipulated (n5 29) or CD8-depleted (n5 24) or CD34-selected









Number 14 27 19
Age (M  SD) 56  13 55  11 55  7 NS
Sex NS
Males 10 18 15
Females 4 9 4
Disease NS*
AML 1 1 3
CML 2 2 1
MDS 1 7 2
Myelofibrosis 0 1 0
NHL 5 9 6
HD 1 0 1
CLL 1 1 0
MM 1 5 3
RCC 2 1 3
Disease status NS
CR 5 3 4
No CR 9 24 15
Prior autologous HCT NS
Yes 6 13 10
No 8 14 9
Donor type NS**
HLA-identical sibling 10 13 6
Other related 1 1 1
HLA-identical unrelated 3 13 12
ABO compatibility NS
Identical 9 14 11
Major mismatch 4 7 2
Minor mismatch 1 6 6
Conditioning regimen NS
2 Gy TBI 6 11 7





None 5 13 11
CD8 depletion 6 12 6
CD34 selection 3 2 2
Baseline hemoglobin (g/dL) 11.2  1.4 10.5  2.3 10.2  1.4 0.3079
Baseline serum
creatinine (mg/L)
Day 0 (M  SD) 9.5  4.1 9.6  3.9 11.5  4.7 NS
Day 28 (M  SD) 11.5  2.9 12.4  3.7 14.6  5.9 NS
AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS,
myelodysplastic syndrome; NHL, non-Hodgkin’s lymphoma; HD, Hodg-
kin’s disease; CLL, chronic lymphocytic leukemia; MM, multiple myeloma;
RCC, renal cell carcinoma; CR, complete remission; TBI, total-body irradi-
ation; M, mean; NS, not significant.
*Comparison between myeloid malignancies, lymphoid malignancies, and
solid tumors.
**p 5 0.077.
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trigger values for RBC and platelet transfusion were 8.0 g/dL and
15  109/L, respectively. Granulocyte colony-stimulating factor
(G-CSF) (5 mg/kg/d) was administered when the granulocyte
count was below 1.0  109/L. The Ethics Committee of the Uni-
versity of Liege approved the study protocols for NMHCT and
rHuEPO therapy. Written informed consent was obtained from
all patients.
RHuEPO therapy
The first 14 NMHCT recipients did not receive rHuEPO (control
group) and were previously reported [33]. For the prospective
phase II trial, we decided to start rHuEPO on day 30 (EPO group
1, n 5 27), because we had previously shown that this approach
was very effective after myeloablative conditioning and transplan-
tation of autologous [20,39] or allogeneic [18] HCT. If there was
an active complication (infection, GVHD, etc.) on day 30, the in-
troduction of rHuEPO was delayed until it resolved. Hence the
median day for onset of rHuEPO therapy was day 32 in this group.
After observing that the nonmyeloablative conditioning regimen
caused only mild myelosuppression that would probably not ham-
per the efficacy of rHuEPO, the protocol was amended so that
rHuEPO was then scheduled to start on day 0 in a third cohort
of 19 patients (EPO group 2). rHuEPO (Neorecormon, Roche,
Basel, Switzerland) was administered subcutaneously once
weekly at a dose of 500 U/kg/wk with the aim of achieving hemo-
globin (Hb) levels of 13 g/dL. A major response (responder) was
defined by an Hb increment greater than 2 g/dL without transfu-
sion needs [14]. The response was considered as complete (correc-
tor) when the Hb reached the target value of 13 g/dL. Once the
target Hb (13 g/dL) was achieved, the dose of rHuEPO was re-
duced so as to use the lowest dose capable of maintaining the
Hb between 12 and 14 g/dL. If no major response was achieved
after a total of 80 days of treatment, rHuEPO was discontinued.
Patients received intravenous iron (Venofer, [Vifor, St. Gallin,
Switzerland] 600 mg in 3 divided weekly doses) if transferrin sat-
uration fell below 20%, unless the target Hb was already achieved.
Control patients never received intravenous iron.
Laboratory analyses
Laboratory data were monitored weekly. Complete blood counts
were determined in an Advia cell counter (Bayer, Tarrytown,
NJ, USA). Serum erythropoietin (EPO) levels were measured
just before treatment by a commercially available radioimmunoas-
say (Incstar Corp., Stillwater, MN, USA). Based on regression
equations obtained in appropriate reference subjects between
Hct on the one hand and log (EPO) on the other, predicted log
(EPO) values were derived for each Hct and O/P ratios of ob-
served/predicted EPO values were calculated [17]. The mean (
SD) EPO O/P ratio in a cohort of 31 normal donors was 1.03 
0.08. Serum soluble transferrin receptor (sTfR), a quantitative
measure of total erythropoietic activity, was measured by a com-
mercially available ELISA (R&D, Minneapolis, MN, USA). Nor-
mal values range from 3000 to 7000 mg/L. Serum iron, transferrin
saturation, and ferritin were measured by routine methods. The de-
gree of donor chimerism was assessed on days 28 and 42 post-
transplant in myeloid cells and T cells using fluorescence in situ
hybridization (FISH) with X- and Y- specific probes in case of
sex mismatch or PCR-based analysis of polymorphic microsatel-
lite regions in case of sex match.Statistical analysis
To ensure better homogeneity of the results, Hb, sTfR, and retic-
ulocytes were normalized relative to their value on the day of
transplantation. Unpaired and paired Student’s t-tests as well as
two-way ANOVA (using EPO group and time as variables) were
used to compare parameters in the 3 groups. Welsh’s correction
was used in case of unequal variance. In the first month posttrans-
plant, patients in EPO group 1 received no rHuEPO and were thus
considered as controls. To increase the statistical power of the
study, the protocol scheduled for a comparison of patients
receiving rHuEPO from day 1 posttransplant (EPO group 2) with
patients receiving no rHuEPO during this period (control group
þ EPO group 1). After the first month, comparisons were made
between the control group and either patients in EPO group 1 or
patients in EPO group 2. Number of transfusions in the same group
over time or in different groups of patients was compared using
Wilcoxon matched pair or Mann-Whitney U tests, respectively.
Times to response to rHuEPO therapy were studied by life-table
analyses and Wilcoxon rank tests were used for comparisons be-
tween groups. For patients included in the control group, time to
achieve Hb levels of 12 and 13 g/dL as well as time to achieve
a 2 g/dL Hb increment were calculated both from day 0 (for com-
parison with EPO group 2) and from day 30 (for comparison with
EPO group 1) after HCT. Patients who experienced graft rejection
(n 5 2), severe hemolysis or hemorrhage (n 5 8), and/or progres-
sion of their disease (n5 9) were censured at time of these events.
In particular, all patients with graft failure or disease progression
rapidly developed hematopoietic failure with neutropenia and
renewed transfusion dependence. Clinical variables associated
with response to rHuEPO were first analyzed by c2 tests. Univariate
as well as multivariate (incorporating variables identified as signif-
icant in univariate analysis) Cox regression models were then per-
formed. Statistical analyses were carried out with Graphpad Prism
(Graphpad Software, San Diego, CA, USA) and SAS (SAS Institute,
Cary, NC, USA) software.
Results
Erythropoiesis
Graft composition and speed of engraftment were not sig-
nificantly different among the 3 groups (Table 2). There
was no significant difference in platelet or neutrophil counts
throughout the posttransplant course between patients re-
ceiving rHuEPO or not. In the first 30 days posttransplant,
sTfR (p 5 0.0034), reticulocytes (p 5 0.0001), and Hb
(p! 0.0001) values were significantly higher in EPO group
2 (rHuEPO from day 0) compared to untreated patients
(control group and EPO group 1) (Fig. 1). Between day
30 and day 120, whereas erythropoiesis (as assessed by
sTfR) remained stable in the control group, it expanded
very rapidly above the upper normal limit for sTfR in the
2 cohorts of patients receiving rHuEPO (p ! 0.0001)
(Fig. 1). Reticulocytes similarly increased significantly
compared to controls (p 5 0.0173). This expansion of
erythropoietic activity translated into significantly more fa-
vorable Hb values (p ! 0.0001). Because it was measured
844 G. Vanstraelen et al./ Experimental Hematology 34 (2006) 841–850Table 2. Graft composition and hematopoietic recovery
Control group EPO group 1 EPO group 2
Graft composition (mean  SD)
CD34þ cells ( 106/kg) 5.66  2.75 5.99  3.06 5.39  2.65
BFU-E ( 104/kg) 101.1  71.7 131.3  80.3 109.6  55.9
Days to 1% reticulocytes (median [range]) 16 [1–38] 15 [1–42] 11 [1–38]
Days to last RBC transfusion (median [range]) 6 [1–25] 13 [1–53] 11 [1–62]
Days to 20 109/L platelets (median [range]) 4 [1–19] 6 [1–31] 6 [1–31]
Days to 100  109/L platelets (median [range]) 12 [1–43] 16 [1–62] 14 [1–62]
Days to last platelet transfusion (median [range]) 5 [1–30] 5 [1–25] 5 [1–25]
Number of days of G-CSF (median [range]) 3 [0–10] 6 [0–17] 5 [0–17]
Days to 0.5  109/L neutrophils (median [range]) 7 [1–24] 5 [1–14] 4 [1–13]
Days to 1.0  109/L neutrophils (median [range]) 11 [1–38] 8 [1–22] 8 [1–22]
‘‘Days to’’ means days from transplant to the event. Day 1 means that either counts never decreased below stated level or transfusions were never admin-
istered. All differences are nonsignificant.immediately after the conditioning regimen in EPO group 2
whereas it was measured 4 weeks later in EPO group 1, the
pretreatment O/P ratio was higher in EPO group 2 (1.11 
0.22 vs 0.91  0.25, p 5 0.0302).
Clinical response
In the first month after transplantation, mean  SD number
of RBC transfusions was 1.7  0.4 in patients who did not
receive rHuEPO (control group þ EPO group 1, very sim-
ilar in the 2 groups) and 0.5  0.3 in patients who received
it starting on day 0 (EPO group 2) (p 5 0.0169). Between
days 30 and 100, there were 1.6  0.7 RBC transfusions in
controls vs 1.2  0.4 in patients receiving rHuEPO (p 5
0.5919). Between days 100 and 180, the figures were 0.7
0.5 in controls vs 0.5  0.3 in patients receiving rHuEPO
(p 5 0.8186). Clinical response with reduction in transfu-
sion needs was thus observed only in the group of patients
receiving rHuEPO starting on the day of transplantation.
During the first month posttransplant, the mean transfusion
cost decreased from 302  422 EUR in patients receiving
no rHuEPO to 89  207 EUR in patients receiving rHuEPO
(p5 0.022). However, because of the monthly cost of treat-
ment at full dose (1276 EUR/patient), rHuEPO remains
much more expensive than iterative transfusion.
The K-M probability of achieving a Hb increment of at
least 2 g/dL at 8, 12, or 16 weeks was 14%, 14%, and 14%
in controls, vs 28%, 64%, and 64% respectively in EPO
group 2 (p 5 0.0082) and 19%, 19%, and 69% respectively
in EPO group 1 (p 5 0.0125) (Fig. 2). The probability of
achieving a Hb value of 13 g/dL at 8, 12, and 16 weeks
was 0%, 0%, and 0% in controls, vs 17%, 34%, and 45%
in EPO group 2 (p 5 0.0103) and 8%, 26%, and 49% in
EPO group 1 (p 5 0.0031) (Fig. 2). Eventually, 17% of
the patients in the control group vs 56% in EPO group 2
(p 5 0.0145) and 64% in EPO group 1 (p 5 0.0031)
achieved an Hb value of 13 g/dL (Fig. 2). This was obtained
after a median of 21 weeks in both EPO groups. These
comparable responses among the 2 groups were achieved
despite a slight difference between pretreatment Hb values(9.3  1.3 in group 1 (day 28 posttransplant) vs 10.2  1.4
in group 2 (day 0 of transplantation), p 5 0.0359).
Similar proportions of patients needed intravenous iron
supplementation in EPO group 1 (51%) and in EPO group
2 (42%). All patients in all the 3 groups were alive at day
120 posttransplant.
Variables associated with response to rHuEPO
Because the response rate observed after NMSCT was sig-
nificantly lower than the one obtained after HCT with
a myeloablative conditioning regimen, we attempted at
identifying factors that could be associated with response
to rHuEPO therapy. We considered all patients receiving
rHuEPO and classified them in 2 groups according to
whether they achieved a major ($2 g/dL Hb increment)
or a complete (Hb $ 13 g/dL) response or not. Variables
analyzed were baseline clinical characteristics (age, sex,
prior autologous HCT, disease and disease status, condi-
tioning regimen, graft manipulation, donor type, ABO com-
patibility, HLA matching) and biological parameters (EPO
O/P ratio, Hb, sTfR, retics, creatinine, serum iron, transfer-
rin saturation, ferritin, platelets, neutrophils), events occur-
ring on rHuEPO therapy (aGVHD, CMV and other
infections, intravenous iron administration), and posttrans-
plant myeloid and T-cell chimerism (Table 3). The median
T-cell chimerism was 75% on day 28 and 75% on day 42.
To obtain the optimal cutoff for T-cell and myeloid chime-
rism values, we first examined several cutoffs (50%, 60%,
70%, 80%, 90%, and 95%) on days 28 and 42 in univariate
analysis. The optimal cutoff was then selected for use in
multivariate analysis.
Clinically relevant prognostic factors were first tested by
Student’s t-tests. Age, sex, previous autologous transplant,
disease, disease status, conditioning regimen, and renal
function did not impact on response (data not shown, all
p valuesO 0.10). A conditioning regimen including TBI or
CD8 depletion of the graft generated lower probabilities of
major or complete response to rHuEPO therapy (Table 3).
The degrees of myeloid or lymphoid chimerism on days 28





























































































































































































































Figure 1. Hb levels, reticulocyte counts, and sTfR levels after transplantation. Values are normalized relative to their value on the day of transplantation. The
left panels provide the evolution in EPO group 1 (rHuEPO started on day 30) and right panels the evolution in EPO group 2 (rHuEPO started on day 0).
p values are given for comparisons with the control group at any particular time point by Student’s t-tests (*!0.05, **!0.01, ***!0.001).and 42 were also important determinants of response to
rHuEPO. Patients with a myeloid chimerism above 90%
and even more so T-cell chimerism above 60% had a signifi-
cantly higher probability of achieving a major or complete re-
sponse (Table 3). No other factor, and in particular not
baseline EPO, was associated with response (Table 3).
Univariate Cox regression models were then performed
with all variables listed above, including all biological pa-rameters as measured on days 0 and 28 of rHuEPO treat-
ment. Factors selected based on these univariate analysis
(TBI, CD8 depletion, day-42 T-cell chimerism, day-42 my-
eloid chimerism, Hb and platelets on day 0 of rHuEPO ther-
apy, reticulocytes on day 28 of rHuEPO therapy for major
response; and TBI, CD8 depletion, day-42 T-cell chimerism
for complete response) were then tested in multivariate Cox
models (Table 4). T-cell chimerism above 60% on day 42













N patients at risk 
Control group 14 14 13 13 12 12
Epo group 1 27 25 18 9 5 5
N patients at risk 
Control group 14 14 13 13 12 12
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Control group (N = 14)
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Control group (N = 14)
Epo group 2 (N = 19)
p=0.0031
N patients at risk 
Control group 14 14 14 14 14 14
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Figure 2. Kaplan-Meier plots of time to major response (Hb increasing by 2 g/dL 5 Hb response) and time to complete response (Hb $ 13 g/dL 5 Hb
correction) from day of transplantation. The left panels provide the evolution in EPO group 1 (rHuEPO started on day 30) and right panels the evolution
in EPO group 2 (rHuEPO started on day 0), compared to the control group.was the variable most associated with Hb response (p 5
0.0034) or Hb correction (p5 0.0217). Only lower baseline
Hb levels were also associated with Hb response (p 5
0.011) but not with Hb correction.
Discussion
In this study, we examined the effect of rHuEPO therapy
after allogeneic transplantation with a nonmyeloablative
conditioning regimen. The majority of NMSCT patients
responded to rHuEPO with Hb increments greater than 2
g/dL and correction of anemia. This was clearly preceded
by stimulation of erythropoietic activity as assessed by
sTfR levels, whereas reticulocyte counts, as in other
rHuEPO trials after HCT [20,32], were less reliably
increased. Although we did not formally compare these
results with response to rHuEPO after conventional trans-
plantation [18,32], responses appeared slower and overall
response rates lower in NMSCT recipients. Obviously,there are major differences, such as age, disease status, pre-
vious auto-HCT, and conditioning regimen, between
NMSCT and conventional transplants that could limit the
scope of comparisons. Nevertheless, as these variables
were found to have no impact on response to rHuEPO in
this as well as other studies, potential explanations can still
be examined.
The reason for this discrepancy between NMSCT and
conventional transplants could relate to differences in the
pathophysiology of endogenous EPO production. Indeed,
we have previously shown that, while endogenous EPO
levels became rapidly inappropriately low for at least
several months after conventional transplants [16–20], they
remained adequate during the whole posttransplant course
after NMSCT [33]. Therefore rHuEPO could be predicted
to be less efficient after NMSCT. However, among NMSCT
patients, lower endogenous EPO levels were not associated
with better response to rHuEPO therapy. On the other hand,
as previous studies had shown that after conventional
847G. Vanstraelen et al./ Experimental Hematology 34 (2006) 841–850transplantation the benefit of rHuEPO therapy was minimal
when it was given early posttransplant [21–32] but could
be optimized when started after day 30 [32], we first admin-
istered rHuEPO starting on day 30 after the transplant. How-
ever, as the degree of myelosuppression after NMSCT was
mild [13], we also started rHuEPO therapy on the day of
transplantation in another group of patients, achieving com-
plete Hb correction at similar speed and frequency. Further-
Table 3. Clinical variables analyzed (see text) by t-tests
for association with major (Hb þ2 g/dL) and complete
(Hb $ 13 g/dL) response to rHuEPO
Major response Complete response
n (%) p value n (%) p value
TBI
Yes 19 (46%) 0.0233 14 (34%) 0.0047
No 5 (100%) 5 (100%)
Graft manipulation
No 17 (71%) 0.0380* 13 (54%) 0.0926**
CD8 depletion 5 (28%) 4 (22%)
CD34 selection 2 (50%) 2 (50%)
Donor type
Related 10 (45%) 0.3820 9 (41%) 0.9580
Unrelated 14 (58%) 10 (42%)
ABO compatibility
ABO identical 14 (56%) 0.5700 11 (44%) 0.6850
Not ABO identical 10 (48%) 8 (38%)
HLA
Matched 21 (51%) 0.7100 16 (39%) 0.3680
Mismatched 3 (60%) 3 (60%)
EPO O/P ratio
!0.9 9 (52%) 0.9360 13 (54%) 0.0642
$0.9 15 (52%) 6 (27%)
Acute GVHD (grade II-IV)
Yes 10 (56%) 0.7120 7 (39%) 0.7890
No 14 (50%) 12 (43%)
CMV infection
Yes 9 (39%) 0.0765 9 (41%) 0.9580
No 15 (65%) 10 (42%)
Other infection
Yes 7 (41%) 0.2520 7 (39%) 0.7890
No 17 (59%) 12 (43%)
T-cell chimerism (day 28)
$60% 20 (69%) 0.0029 15 (52%) 0.0608
!60% 4 (24%) 4 (24%)
T-cell chimerism (day 42)
$60% 20 (71%) 0.0018 16 (57%) 0.0093
!60% 4 (23%) 3 (18%)
Myeloid chimerism (day 28)
$90% 21 (63%) 0.0131 16 (48%) 0.1150
!90% 3 (23%) 3 (23%)
Myeloid chimerism (day 42)
$90% 21 (61%) 0.0046 16 (47%) 0.2480
!90% 3 (27%) 3 (27%)
*p 5 0.0081 for no manipulation vs any manipulation, and p 5 0.0079 for
CD8 depletion vs all others.
**p 5 0.0640 for no manipulation vs any manipulation, and p 5 0.0350
for CD8 depletion vs all others.more, transfusion requirements were decreased only in the
first month posttransplant if rHuEPO was started on day 0,
a period when endogenous EPO levels are exaggerated for
the degree of anemia. All these findings indicate that, after
NMSCT, the pathophysiology of endogenous EPO produc-
tion does not account for response to rHuEPO therapy.
There is only a single other study investigating the im-
pact of rHuEPO therapy starting on day 1 after NMSCT
in 20 patients [37]. All of them, vs only 63% of controls,
achieved an Hb level greater than 11 g/dL after a median
of 30 days and 70% of them, vs only 19% of controls,
maintained it in the second month. Comparison with our
trial is difficult because they did not report on more stan-
dard response criteria (proportion of patients achieving
Hb response or Hb correction), used a more intensive con-
ditioning regimen, and provided systematic oral iron sup-
plementation compared to more targeted intravenous iron
supplementation in our trial. For patients receiving RBC
transfusions, their use of rHuEPO was associated with
a trend towards reduced requirements [37]. The same au-
thors also previously showed that RBC transfusion needs
after NMSCT correlated inversely with pretransplant Hb
levels [36]. In our trial, we found that baseline Hb inversely
correlated with response to rHuEPO therapy. However, the
latter may be explained in part by methodological reasons,
because more anemic patients had more opportunity to in-
crease their Hb by at least 2 g/dL before per-protocol
rHuEPO dose reductions could take place.
We sought to identify patient and transplant characteris-
tics associated with response. A major ABO mismatch be-
tween donor and recipient is classically associated with
delayed recovery of erythropoietic activity because of di-
rect inhibition of donor erythroid progenitors and precur-
sors by residual recipient ABO antibodies [40], but this
did not impair response to rHuEPO. Previous reports have
also indicated that a major ABO mismatch does not prevent
appropriate response to rHuEPO [41]. Because of the major
inflammatory response they elicit, infections often result in
a delay or loss of response to rHuEPO therapy in other set-
tings [14,17,42], but not in our NMSCT patients. The use of
an unrelated donor increases the risk of infection as well as
of acute GVHD, a complication associated with further
inhibition of endogenous EPO production [16,17,43] and
a cytokine storm potentially inhibiting marrow
Table 4. Multivariate analysis of probability of response to rHuEPO
RR 95% CI p value




Baseline Hb (continuous) 0.63 0.48–0.83 0.0011
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rHuEPO in our patients.
Most interestingly, the degree of donor chimerism was
of utmost importance for response to rHuEPO. Although
a high degree of myeloid donor chimerism (O90%) was
also associated with better response, a high proportion of
lymphocytes of donor origin was the only variable associ-
ated both with Hb response and Hb correction in multivar-
iate analysis. The optimal cutoff value and timing were
found to be donor T-cell chimerism greater than 60% on
day 42. Use of TBI in the conditioning regimen and CD8
depletion of the graft were associated with poorer response
to rHuEPO in univariate but not multivariate analysis, most
probably because their effects were mostly related to the
lower chimerism levels they generated. One can only spec-
ulate on the potential explanations for this observation. One
attractive hypothesis is that erythropoietic progenitors and
precursors, which are largely of donor origin soon after
NMSCT [45], could be inhibited by residual recipient lym-
phocytes. These lymphocytes could become activated
against donor antigens, thereby also secreting excess
amounts of inflammatory cytokines that could in turn in-
hibit marrow erythropoietic activity [44]. The higher the
proportion of recipient lymphocytes (decreasing chime-
rism), the stronger this inhibitory effect could be. This hy-
pothesis could be further supported by the fact that patients
receiving CD8-depleted grafts responded less well to
rHuEPO therapy. On the other hand, as T-cell chimerism
is generally immediately fully of donor origin after alloge-
neic transplantation with a myeloablative conditioning reg-
imen [46,47], the absence of such an inhibitory effect of
residual recipient lymphocytes could also provide a reason-
able explanation on why the response rate to rHuEPO ther-
apy is much higher after conventional transplantation. An
alternative explanation could be that recently irradiated
marrow may be less responsive to cytokine stimulation
and that lower-level chimeras could require proportionally
more recovery from irradiated marrow compared with
high-level chimeras. However, this would apply to myeloid
rather than lymphoid chimerism.
Our phase II trial has provided proof of principle and
preliminary efficacy data for a rational use of rHuEPO after
NMHCT by showing Hb responses as well as a reduction in
transfusion needs in the first 30 days posttransplant. One
could argue that our patient population was quite heteroge-
neous for diagnosis, disease stage, conditioning regimen,
donor type, and graft manipulation. This is true but we
clearly showed that none of these factors significantly influ-
enced response to rHuEPO. In addition, all previous studies
of rHuEPO after HCT have included such heterogeneous
groups of patients on the basis of the lack of any evidence
that these pretransplant characteristics significantly affected
posttransplant erythropoietic activity. This is even more ev-
ident in all major studies of rHuEPO given for the treatment
of cancer- or chemotherapy-associated anemia. On theother hand, one could argue that an average transfusion
rate of 4 U over 6 months as observed in our untreated
NMSCT recipients is quite moderate and that the clinical
utility of rHuEPO would be limited. However, there is
a need for effective prevention and the benefits of rHuEPO
therapy are not limited to transfusion avoidance. To avoid
the potential difficulties in interpreting the impact of
rHuEPO therapy after transplantation, it is thus now justi-
fied to develop prospective, randomized trials that should
investigate clinical endpoints previously shown to be im-
proved by rHuEPO therapy in other settings, such as trans-
fusion requirements and quality of life. In order to
demonstrate a real impact on transfusions, our recommen-
dation for such trials would be to start rHuEPO therapy
on day 0 of the transplant at the standard dose of 500 U/
kg/wk, while adopting a strategy aiming at optimizing T-
cell chimerism early on.
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